- 2015-12-21Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
- 2015-12-21Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
- 2015-12-21Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
- 2015-12-21Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
- 2015-12-21Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designat
-
- 2015-12-21ADK在优酷和YouTube上发布主题为“遇见故乡”的系列视频，介绍日本的区域文化
- 2015-12-21Tommy Hilfiger宣布Gigi Hadid担任其全球品牌大使
- 2015-12-21世界十大石油巨头齐聚北京3月全球最大石油展
- 2015-12-21Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnose
- 2015-12-21Oral REVLIMID® Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnose
-
